- Home
- URGN vs REKR Comparison
URGN vs REKR Comparison
Compare URGN & REKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- REKR
- Stock Information
- Founded
- URGN 2004
- REKR 2017
- Country
- URGN United States
- REKR United States
- Employees
- URGN N/A
- REKR N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- REKR Telecommunications Equipment
- Sector
- URGN Health Care
- REKR Telecommunications
- Exchange
- URGN Nasdaq
- REKR Nasdaq
- Market Cap
- URGN 181.2M
- REKR 153.5M
- IPO Year
- URGN 2017
- REKR N/A
- Fundamental
- Price
- URGN $13.84
- REKR $1.25
- Analyst Decision
- URGN Strong Buy
- REKR
- Analyst Count
- URGN 8
- REKR 0
- Target Price
- URGN $29.00
- REKR N/A
- AVG Volume (30 Days)
- URGN 4.3M
- REKR 4.0M
- Earning Date
- URGN 08-12-2025
- REKR 08-13-2025
- Dividend Yield
- URGN N/A
- REKR N/A
- EPS Growth
- URGN N/A
- REKR N/A
- EPS
- URGN N/A
- REKR N/A
- Revenue
- URGN $91,871,000.00
- REKR $45,448,000.00
- Revenue This Year
- URGN $36.65
- REKR $8.68
- Revenue Next Year
- URGN $88.35
- REKR $21.45
- P/E Ratio
- URGN N/A
- REKR N/A
- Revenue Growth
- URGN 8.98
- REKR 17.97
- 52 Week Low
- URGN $3.42
- REKR $0.62
- 52 Week High
- URGN $18.15
- REKR $2.67
- Technical
- Relative Strength Index (RSI)
- URGN 64.90
- REKR 51.53
- Support Level
- URGN $13.26
- REKR $1.19
- Resistance Level
- URGN $13.94
- REKR $1.34
- Average True Range (ATR)
- URGN 0.91
- REKR 0.09
- MACD
- URGN -0.08
- REKR -0.00
- Stochastic Oscillator
- URGN 44.44
- REKR 55.77
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About REKR Rekor Systems Inc.
Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which a majority of its revenue comes from the United States.